Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: NOVEL

Thymulin

Plain-language summaryIntrigue 50 / 100

Thymulin is a 9-amino-acid zinc-dependent thymic hormone that regulates T-cell development. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

A 1970s thymic nonapeptide with legitimate immunology history but limited current research priority

Thymulin has been in the literature for over fifty years, which should tell you something. Bach and Goldstein’s groups first isolated it from thymic epithelial extracts in the 1970s, and while the zinc-dependent activation story is genuinely interesting biochemistry, the compound hasn’t really moved the needle in the decades since. Thats a long time to stay at the preclinical fringe.

Here’s the thing about the mechanism: thymulin requires bound zinc to be biologically active, and the apopeptide alone does essentially nothing. The Zn-thymulin complex is the active form, which creates a practical wrinkle that’s underappreciated in the peptide community. That zinc-dependency makes it a defensible model for studying metallopeptide pharmacology, and we think that’s actually its most legitimate research use in 2025. But the biology of thymic epithelial signaling and T-cell differentiation is well-mapped territory. There’s nothing paradigm-altering in the mechanism here.

The differentiation problem is real and it’s the biggest drag on the score. Thymosin alpha-1, the better-known thymic peptide, has reached regulatory approval in multiple jurisdictions and carries a substantially larger clinical trial base. If your research program touches thymic immunomodulation or infection adjunct applications, thymulin is not the first compound you’d reach for. It competes in a class where thymosin alpha-1 clearly outpoints it on evidence and thymosin beta-4 fragments have more active current interest. One of several, not the obvious choice.

The evidence base earns some credit. Multi-decade preclinical work across multiple independent labs is worth something, and it puts thymulin above single-consortium peptides like Epitalon. There’s limited Phase 2 data in chronic infections and some autoimmune contexts, which is real. But limited Phase 2 data and no regulatory follow-through after fifty years is a signal. The Eastern European literature cluster pattern that plagues other thymic peptides shows up here too, and it introduces replication concerns you cant fully dismiss.

What we do find interesting is the aging-thymus angle. Thymic involution is a genuine biological problem, thymulin levels decline with age alongside thymic output, and theres a plausible rationale for studying thymulin or synthetic analogs as probes of age-related immune deterioration. Some recent work from Brazilian groups on nonapeptide analogs with modified zinc-chelating residues is actually more compelling than the parent compound. That derivative work is worth watching; the original compound less so.

Honestly, for most investigators in 2025, thymulin is background reading rather than an active target. It earns its place in a complete immunology reference library, and it’s useful context when studying thymic peptides as a class. But its not a priority bench object unless you already have a thymus-specific program and need the original compound as a reference standard.

Novelty

28

Mechanism promise

38

In-category differentiation

25

Evidence quality

40

Translational signal

30

Research bench value

45

Rationale Thymulin is a mature compound with well-established mechanism and multi-decade multi-lab preclinical work, but limited clinical translation and clear competition from thymosin alpha-1, which has actual regulatory recognition in several jurisdictions. The zinc-dependency biology and aging-thymus angle provide modest bench value but don’t overcome the compound’s age, weak differentiation, and thin human evidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Zinc-dependent thymic nonapeptide

A zinc-dependent endogenous thymic nonapeptide secreted by thymic epithelial cells with T-cell maturation activity.

Abstract

Thymulin (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn; molecular weight 857) is a nonapeptide originally isolated by Bach and Goldstein groups in the 1970s. The peptide is endogenously secreted by thymic epithelial cells and requires bound zinc for biological activity. Pharmacology includes promotion of T-cell differentiation, modulation of cytokine balance, and effects on autoimmune and inflammatory processes. The compound has been studied in chronic infections, autoimmune diseases, and cancer immunotherapy adjunct applications, with limited Phase 2 evidence. Available as research peptide. Doses are typically 100 to 1000 micrograms per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-128Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Latrepirdine (Dimebon)

Our opinion on this compoundRetracted or disproven

30/100

High-profile phase 3 failure; residual probe value for multi-target receptor pharmacology only

Look, Latrepirdine is one of the most instructive failure stories in CNS pharmacology, and not in a way that makes it a compelling research target today. The 2008 Doody et al. phase 2 trial looked genuinely exciting: a small Russian cohort, significant ADAS-cog improvements, a multi-target receptor profile that nobody had properly characterized, and a mitochondrial protection story that felt like it could explain everything. Pfizer and Medivation saw it too, licensed it, and ran two large phase 3 trials. Both failed. CONNECTION and CONCERT were well-powered, well-designed trials and they found nothing. That’s not a marginal miss; thats a decisive refutation of the clinical hypothesis.

The mechanism story never really resolved. The proposed mitochondrial protective effects, seen in some Bhagya Bhardwaj and Bhatt lab preclinical work around 2009-2010, were speculative and never validated in humans. The receptor profile is genuinely broad: H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2. Interesting on paper. In practice, non-selective polypharmacology of this kind is hard to interrogate cleanly, and the carboline scaffold doesn’t give you the kind of selectivity you’d want for mechanistic studies. You can’t easily tease apart which receptor is doing what.

We think the only honest argument for latrepirdine as a research compound in 2025 is as a pharmacological probe for studying multi-receptor interaction effects in the receptor profile it occupies. Its beta-carboline scaffold is at least structurally distinct, and theres a small body of work using it to study 5-HT6 and 5-HT5A receptor contributions in mixed-target paradigms. For investigators specifically working on receptor polypharmacology or building multi-target binding models, it has some real but narrow utility. The compound is commercially available from several RUO vendors, synthesis is straightforward, and the pharmacokinetics are reasonably well characterized.

What we don’t like: the translational arrow points firmly backwards. The mitochondrial story is unvalidated and the primary indication collapsed publicly. The novelty is minimal, the differentiation from other available probes in its receptor class is low, and the evidence base that actually exists is evidence of failure. That phase 2 signal is almost certainly a statistical artifact or a trial design artifact; the Russian cohort, the small N, the endpoint choices. Investigators who want to study the receptor space latrepirdine occupies have better, cleaner probes available. This compound belongs in the case-study file, not on the active screening list.

Novelty

25

Mechanism promise

30

In-category differentiation

20

Evidence quality

55

Translational signal

15

Research bench value

40

Rationale Phase 3 CONNECTION and CONCERT trials decisively refuted the phase 2 signal in Alzheimer disease, collapsing the primary translational story; the compound retains narrow utility as a multi-target receptor probe by virtue of its carboline scaffold and unusual receptor breadth, but a serious investigator has no strong reason to prioritize it over better-validated tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Multi-target antihistamine / mitochondrial protectant

A Russian antihistamine repurposed for Alzheimer disease and Huntington disease; phase 3 trials failed despite encouraging phase 2 results.

Abstract

Latrepirdine (Dimebon, dimebolin; CAS 3613-73-8; molecular formula C21H25N3; molecular weight 319.45) is a tetrahydro-gamma-carboline antihistamine developed in the USSR in the 1960s and approved in Russia for allergic conditions. The compound is a non-selective receptor blocker (H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2). The Alzheimer disease application emerged from drug repurposing screens in the 2000s; preclinical studies suggested mitochondrial protective effects independent of the receptor binding. Phase 2 trial in mild-to-moderate Alzheimer disease (2008) demonstrated significant improvement in ADAS-cog and other endpoints, generating widespread interest. Phase 3 trials (CONNECTION, CONCERT) in 2010-2012 failed to replicate the phase 2 effects, marking one of the highest-profile late-stage failures in CNS drug development. The compound is no longer in clinical development. Used as a research compound for multi-target receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-314Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cutamesine (SA-4503)

Our opinion on this compoundNiche research probe

54/100

Cleanest sigma-1 probe available; real bench utility but modest and mixed clinical results keep the ceiling low

Look, sigma-1 is genuinely interesting biology. It’s not a traditional receptor. It’s a chaperone protein sitting at the mitochondria-associated ER membrane, regulating IP3 receptors, calcium transfer between organelles, and cellular stress responses. When a compound engages sigma-1, you’re not turning a GPCR on or off. You’re modulating a protein that helps the cell manage ER stress and mitochondrial calcium homeostasis. Thats a different kind of pharmacology, and it opens angles that conventional receptor agonism doesn’t reach.

SA-4503 is the cleanest tool you can buy for studying that biology. Ki of roughly 17 nM at sigma-1 with greater than 100-fold selectivity over sigma-2, and minimal off-target binding beyond that. Most sigma-1 ligands are messy. Fluvoxamine hits sigma-1 but it’s primarily an SSRI, so you can’t attribute any effect cleanly. PRE-084 has been used in academic labs but SA-4503 has become the canonical reference compound precisely because the selectivity story is tight. If your hypothesis is sigma-1 mediated, this is the compound you need to run it cleanly.

Here’s the thing: the clinical picture muddies the enthusiasm considerably. The phase 2 ischemic stroke trial (60 mg, starting within 72 hours, 28 days) showed modest improvement. The MDD phase 2 results were mixed. We don’t see the kind of signal here that makes an investigator want to restructure a research program around the target. Sigma-1’s role in neuroprotection has generated decades of preclinical work and the bench-to-clinic arrow is weaker than the mechanistic story implies. That gap is real and honestly we don’t have a clean explanation for it yet.

What keeps the score from dropping further is exactly that bench utility. Sigma-1 has been pulled into COVID-19 biology (the virus binds sigma-1 through the ORF9c protein), neurodegeneration, addiction circuits, and pain processing. If you’re running any of those programs and you want a clean pharmacological probe to dissect sigma-1 contribution, SA-4503 is irreplaceable. It’s not that the compound is exciting in the way that a novel triple agonist or a mitochondrial peptide is exciting. It’s that for a specific class of research questions, its the only rigorous tool.

We think this lands firmly in niche-probe territory. Dont buy it unless sigma-1 is already in your hypothesis. If it is, dont buy anything else.

Novelty

40

Mechanism promise

60

In-category differentiation

68

Evidence quality

50

Translational signal

38

Research bench value

72

Rationale SA-4503 scores primarily on differentiation and bench value: it’s the canonical selective sigma-1 agonist and nothing else comes close on selectivity, which matters if you’re running a sigma-1 program. But the sigma-1 story is decades old, phase 2 results in both stroke and MDD were modest to mixed, and the indication space is specialized enough that most investigators won’t touch it unless sigma-1 is already in their hypothesis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective sigma-1 receptor agonist

A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

Abstract

Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-332Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymogen

Plain-language summaryIntrigue 45 / 100

Thymogen is a synthetic dipeptide (Glu-Trp) immunomodulator developed in Russia, derived from research on thymic hormones. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

37/100

Russian-approved thymic dipeptide with real but geographically isolated evidence and conventional immunomodulatory mechanism

Thymogen is the synthetic Glu-Trp dipeptide, pulled from bovine thymus extract by the fractionation work that produced the broader thymalin literature. It’s a legitimately interesting research object in a narrow sense: two amino acids, modest immunomodulatory activity, and a regulatory approval history that puts it above the purely speculative tier. But we have to be honest about what we’re dealing with here.

The mechanism story is straightforward and not especially exciting. Thymic peptides generally modulate T-cell maturation and cytokine output, and Thymogen does this at the dipeptide level. Thats useful to know, but the actual pharmacology is conventional thymic biology, not a novel axis. Compare it to thymosin alpha-1, which has a much richer literature, phase 2/3 trial experience in HIV and hepatitis, and real credibility in the immunostimulant space. Against that competition, Thymogen is clearly secondary.

The evidence situation is the main drag. The literature is almost entirely Russian-language, produced within a small set of institutes associated with the Khavinson/bioregulator tradition. Regulatory approval in Russia and several former Soviet states means there’s real clinical use, but the methodology behind those approvals is opaque by Western standards. There’s essentially no independent multi-lab replication, no phase 2/3 data by EMA or FDA standards, and no published systematic reviews we can assess with confidence.

What we like: the synthetic dipeptide approach is clean. If someone wants to study minimal thymic signaling molecules as probes for T-cell maturation pathways, Thymogen is small, well-defined, and accessible. That’s genuinely more useful than starting with a crude thymus extract. And the intranasal route is interesting from a delivery standpoint if you’re studying mucosal immune signaling in rodent models.

What we don’t like: the mechanism doesn’t differentiate it from better-studied alternatives in the thymic peptide space. Thymosin alpha-1 exists. Thymopentin exists. The Glu-Trp story hasn’t generated the kind of mechanism-deep papers that would justify prioritizing this over those options for a serious research program. The approved-in-Russia status is worth noting but doesn’t substitute for replication outside that regulatory tradition.

For investigators specifically building out a thymic peptide panel or studying minimal bioactive dipeptides as a structural class, Thymogen has real bench value. For most Western research contexts, the evidence base doesn’t justify leading with it over better-characterized alternatives.

Novelty

48

Mechanism promise

33

In-category differentiation

28

Evidence quality

37

Translational signal

42

Research bench value

30

Rationale Thymogen has regulatory approval within Russia and the FSU but the evidence base is single-consortium and lacks Western replication; mechanism is conventional thymic immunobiology with no novel axis, and thymosin alpha-1 clearly dominates the therapeutic space it occupies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic dipeptide immunomodulator

A synthetic dipeptide (Glu-Trp) developed in Russia as an immunomodulator for infectious and post-surgical immune support.

Abstract

Thymogen is the dipeptide L-glutamyl-L-tryptophan, developed in Russia at the Institute of Bioregulation and Gerontology. The compound was identified through fractionation of thymalin (bovine thymus extract) as one of the active components. Thymogen is approved in Russia and several former Soviet states for infectious diseases, post-surgical immune support, and hematopoietic recovery after chemotherapy. Mechanism includes modest T-cell maturation effects and cytokine modulation. Administered intranasally or intramuscularly. Doses are 100 micrograms per day in 3 to 10 day courses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-129Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Anavex 2-73 (Blarcamesine)

Our opinion on this compoundNovel, promising

60/100

Multi-target sigma-1/muscarinic agonist with genuine Phase 3 Rett syndrome signal and real probe utility in neurodegeneration

Yeah, so blarcamesine isn’t the flashiest thing on the shelf, but it’s doing something that a lot of sigma-1 programs have talked about without actually delivering: it has real clinical confirmation. The EXCELLENCE Phase 3 trial in Rett syndrome reported positive results in 2024, which matters because Rett is a brutal, high-unmet-need condition and the CNS literature is littered with Phase 2 wins that collapse in Phase 3. That it held is worth noting.

The mechanism is where we spend most of our thinking. Sigma-1 receptor is a chaperone protein sitting at the ER-mitochondria interface, involved in calcium signaling, proteostasis, and ER stress modulation. It’s not a classical receptor in the GPCR sense, which makes the pharmacology more complicated and more interesting. Blarcamesine’s sigma-1 affinity sits around 860 nM, which is weaker than cutamesine but still functionally meaningful. What sets it apart is the additional muscarinic M1/M2 activity. Cholinergic deficits are central to Alzheimer’s and Parkinson’s dementia pathology, so hitting both sigma-1 chaperone biology and muscarinic tone simultaneously is a real multi-target rationale, not a coincidence of dirty pharmacology. We like that about it.

The Phase 2 data in Alzheimer’s disease and Parkinson’s disease dementia showed dose-dependent improvements on some cognitive endpoints. Honest take: the AD Phase 2 results were encouraging but not spectacular, and the trial designs had limitations. The Rett syndrome Phase 3 is the strongest evidence pillar right now. That’s a rare disease context with small N, so extrapolating broadly requires caution, but the signal is real and replicated within the program.

As a bench tool, blarcamesine has genuine value for investigators working sigma-1 neuropharmacology or probing ER stress pathways in neurodegeneration models. It’s more pharmacologically interesting than generic sigma-1 ligands precisely because of the muscarinic overlay. If you’re trying to untangle sigma-1-dependent vs. cholinergic contributions to a cellular phenotype, blarcamesine gives you a handle that simpler probes dont. Cutamesine (SA4503) had its Phase 2 stroke trial fail, and fluvoxamine’s sigma-1 activity is inseparable from its SERT pharmacology. Blarcamesine is the most clinically advanced compound with a specific dual sigma-1/muscarinic profile, which gives it differentiation that isnt just theoretical.

What we dont love: the sigma-1 field has been promising a lot for twenty-plus years and the clinical wins have been narrow and indication-specific so far. The Alzheimer’s program needs Phase 3 to answer the real question. But the 2024 Rett result adds legitimacy to the mechanism, and the compound’s probe utility in ER stress and cholinergic neurobiology is solid. For a lab working neurodegeneration or protein homeostasis, this earns a place on the shelf.

Novelty

55

Mechanism promise

65

In-category differentiation

62

Evidence quality

60

Translational signal

62

Research bench value

55

Rationale Blarcamesine’s dual sigma-1/muscarinic profile is meaningfully differentiated from single-target sigma-1 ligands, and the 2024 Phase 3 EXCELLENCE trial positive result in Rett syndrome is the clearest clinical confirmation in its class; however, the Alzheimer’s Phase 2 data is modest and sigma-1 receptor biology, while genuinely interesting, has been pursued since the 1990s, which constrains novelty and mechanism scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sigma-1 agonist + muscarinic modulator

A sigma-1 agonist with muscarinic acetylcholine receptor activity; investigated for Alzheimer disease, Parkinson dementia, and Rett syndrome.

Abstract

Anavex 2-73 (blarcamesine, AVN-101; CAS 195615-83-9; molecular formula C16H21NO; molecular weight 243.34) is a multi-target sigma-1 agonist with muscarinic acetylcholine receptor activity, developed by Anavex Life Sciences. Sigma-1 affinity is approximately 860 nM (lower than cutamesine but functionally meaningful); the compound additionally interacts with muscarinic M1 and M2 receptors. Phase 2 trials in Alzheimer disease and Parkinson disease dementia demonstrated dose-dependent improvements in some cognitive endpoints. Phase 3 in Rett syndrome (EXCELLENCE trial) reported positive results in 2024 for select endpoints. Plasma half-life is approximately 14 hours. Used as a multi-target research compound for sigma-1 and muscarinic neuropharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-333Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymopentin

Plain-language summaryIntrigue 50 / 100

Thymopentin is a 5-amino-acid synthetic peptide representing the active region of thymopoietin. Used historically for psoriasis and immune modulation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A mature thymic pentapeptide with real approvals but overshadowed by thymosin alpha-1 across every meaningful axis

Look, thymopentin is a legitimate compound. Arg-Lys-Asp-Val-Tyr, five residues that happen to capture most of thymopoietin’s functional activity in a peptide you can synthesize cleanly and administer subcutaneously. It’s approved in Italy under the Timunox brand, approved in China and several other Asian markets for primary immunodeficiency and hepatitis B support, and has been used in clinical practice for decades. That’s not nothing. The compound is real, the mechanism is real, the human data is real.

The problem is context. When you look at where the thymic peptide space actually sits today, thymopentin is the compound you consider before you remember that thymosin alpha-1 exists. Zadaxin has broader regulatory approval, a more extensive multi-center trial base, better-characterized cytokine kinetics, and a cleaner reputation in the literature. If youre building a research program around thymic biology and T-cell maturation, thymopentin isnt where you start. It’s where you end up if thymosin alpha-1 is unavailable or if you have a specific reason to work with the thymopoietin fragment specifically.

The mechanism is genuinely interesting in principle: the compound appears to promote thymocyte maturation, modulates the CD4/CD8 ratio, and has documented NK cell effects. We don’t dismiss that. But the biology here is well-trodden 1980s immunopharmacology. The trials supporting its approvals predate modern RCT standards. Most of the published literature comes from the era when open-label studies in Eastern European and Asian centers were the standard of evidence, and replication across independent Western lab groups is thin.

What we find most limiting is the differentiation story. The thymic peptide category has a clear hierarchy, and thymopentin isn’t at the top. Thymosin alpha-1 outperforms it on evidence density, indication breadth, and regulatory reach. Thymosin beta-4 fragments occupy a different but increasingly interesting niche. Thymopentin sits in the middle: approved, real, known, but not best-in-class on any axis that matters for a serious research prioritization decision in 2025.

There is some bench value here. If you’re specifically investigating the thymopoietin receptor axis, or studying the minimal active fragment hypothesis in thymic hormone biology, thymopentin is the obvious probe. The five-residue sequence is well-defined and commercially available from reputable peptide vendors, which matters for reproducibility. We think this is where its research merit is most defensible: as a structural probe for a well-mapped biology, not as a frontier target. Honest assessment puts it in the established-mature bucket, useful but not urgent, and a distant second to the compounds that have pushed this field forward more recently.

Novelty

32

Mechanism promise

38

In-category differentiation

25

Evidence quality

48

Translational signal

52

Research bench value

40

Rationale Thymopentin has genuine regulatory standing in Italy and several Asian markets, which pushes evidence and translational scores above peptides stuck in preclinical purgatory, but it sits squarely behind thymosin alpha-1 on differentiation and behind newer immunomodulatory targets on novelty. The thymic peptide biology is real and the pentapeptide design is elegant, but this is 1980s-era pharmacology competing in a field that has moved on.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic pentapeptide of thymopoietin

A synthetic pentapeptide fragment (residues 32-36) of thymopoietin marketed in Europe and Asia for immunomodulation in chronic infections and autoimmune disease.

Abstract

Thymopentin (Timunox, TP-5; Arg-Lys-Asp-Val-Tyr; CAS 69558-55-0; molecular weight 679.78) is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, a thymic hormone. The fragment retains the immunomodulatory activity of full-length thymopoietin. The compound is approved in Italy and several Asian countries for primary immunodeficiency, hepatitis B, atopic dermatitis adjunct, and autoimmune disease support. Mechanism includes T-cell maturation, NK cell modulation, and cytokine balance effects. Administered subcutaneously. Doses are 50 mg three times weekly in clinical use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-130Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
BNN-27

Plain-language summaryIntrigue 70 / 100

BNN-27 is a synthetic neurosteroid derivative of DHEA developed at the BRFAA in Athens. It mimics nerve growth factor (NGF) without activating other DHEA pathways. Investigated for neurodegeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

53/100

Selective TrkA agonist with a genuinely novel scaffold; single-lab evidence limits confidence

BNN-27 is one of the more conceptually elegant compounds we’ve come across in the neurotrophin space. The Gravanis group at the University of Crete has been quietly building a case for a class they call micronutrotropins: small steroid-derived molecules that can engage TrkA, the high-affinity NGF receptor, without triggering p75NTR. That distinction matters more than it might look at first glance. p75NTR is the “dark side” receptor in neurotrophin biology. Under conditions where TrkA is absent or outcompeted, p75NTR can drive apoptosis rather than survival signaling. Separating those two pharmacologically is a genuinely useful thing to do, and not many compounds come close.

What we like here is the scaffold decision. BNN-27 sits on a modified DHEA backbone with a spiroepoxy-thiazoline substituent at C17. It’s a real small molecule, orally bioavailable by rodent data, and CNS-penetrant by inference from the steroid core. That matters because NGF itself is a 26kDa protein with essentially no practical pharmacokinetic profile for CNS applications. Getting TrkA activation from something you can put in a gavage tube, or theoretically formulate for systemic delivery, is the entire pharmacological problem the compound is designed to solve.

The evidence base is where we have to be direct. This is basically a single-lab story. The Gravanis group and Bionature E.A. Ltd have published BNN-27 data in rodent models of diabetic peripheral neuropathy, retinal ganglion cell degeneration, and amyloid-related neurotoxicity. The preclinical results are consistently positive. But consistently positive rodent results from a single consortium are a yellow flag, not a green one. Independent replication has not materialized in any meaningful way, and the methodology is hard to assess from the outside when the compound and the publications come from the same source.

Theres also no clinical data. Not even a phase 1 safety readout. The compound has circulated in the preclinical literature for well over a decade without attracting the external interest needed to push it into human studies. That gap says something about how the broader field has weighted the evidence, even accounting for the capital-intensive nature of novel neurotrophin programs.

For bench researchers, though, BNN-27 has real probe value right now. If your program involves dissecting TrkA-specific survival signaling from p75NTR-mediated death pathways, this is probably your cleanest available small-molecule tool. The selectivity profile is well-characterized in Gravanis lab conditions, and the underlying mechanistic hypothesis is sound. We think investigators working on neurodegeneration models, retinal biology, or diabetic neuropathy should have this on the radar as a tool compound. Just dont treat it as a validated therapeutic lead until someone outside the originating lab replicates the signal.

Novelty

65

Mechanism promise

72

In-category differentiation

60

Evidence quality

25

Translational signal

30

Research bench value

55

Rationale BNN-27 earns its novelty and mechanism scores for the elegant separation of TrkA from p75NTR signaling via a small, orally bioavailable steroid scaffold, a genuinely underexplored pharmacological angle in neurotrophin biology; evidence quality and translational signal are dragged down hard by single-consortium preclinical work and a complete absence of human data after more than a decade in the literature.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic DHEA derivative / NGF mimetic

A synthetic DHEA derivative (17-spiroepoxy DHEA) developed at Bionature E.A. Ltd as a selective TrkA agonist mimicking NGF activity.

Abstract

BNN-27 (17-spiro-(2′-amino-1′,3′-thiazolin-2-yl)-androst-5-en-3-beta-ol) is a synthetic DHEA derivative developed by Bionature E.A. Ltd (Greece) and Achilleas Gravanis’s group for selective activation of TrkA, the high-affinity NGF receptor. The compound is a microneurotrophin: it mimics the NGF/TrkA pathway without binding to the p75 neurotrophin receptor (NTR). Animal studies show neuroprotective effects in models of diabetic neuropathy, retinal degeneration, and Alzheimer disease. The compound has not advanced to large clinical trials. Pharmacokinetics: oral bioavailability is good (steroid scaffold). Sold as research peptide/compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-139Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Beta-Phenylethylamine (PEA)

Our opinion on this compoundNiche research probe

41/100

Endogenous TAAR1 reference compound with poor pharmacokinetics that limit utility beyond the trace amine niche

Look, PEA is genuinely interesting biology and a genuinely limited research tool, and that tension defines the score.

The TAAR1 story is real. Trace amine-associated receptor 1 is one of the more intellectually honest targets to emerge in monoamine pharmacology in the last two decades. It’s a GPCR that responds to endogenous trace amines and modulates dopaminergic and serotonergic neurotransmission without acting directly on those receptors. Thats a mechanistically clean and novel angle, and PEA is the canonical endogenous agonist with a Ki of roughly 700 nM at human TAAR1. The field has genuine traction: ulotaront (SEP-363856), a synthetic TAAR1 agonist developed by Sunovion, completed phase 2 trials in schizophrenia with signal that got people’s attention, and Roche’s RO5166017 has been a workhorse probe in preclinical TAAR1 circuit work. That context upgrades PEA from an old supplement to an endogenous reference compound for an active receptor target.

The problem is the pharmacokinetics, and it’s a serious one. Plasma half-life sits around five to ten minutes owing to rapid MAO-B-mediated degradation. Exogenous oral PEA is largely inactive as a result; meaningful tissue exposure requires MAO-B inhibition, and the selegiline combination used in preclinical trace amine work introduces confounders that make clean TAAR1-attribution difficult. When you compare PEA to synthetic TAAR1 probes with proper selectivity profiles and half-lives long enough to actually run behavioral assays, PEA becomes a baseline reference rather than a primary tool. It tells you where the endogenous system sits; it doesn’t let you interrogate TAAR1-dependent physiology without significant pharmacokinetic caveats layered on top.

The evidence base reflects that limitation honestly. There’s a meaningful multi-lab neurochemistry literature on PEA’s role in trace amine physiology, and some recurring correlational human data, specifically urinary PEA excretion correlations with depressive episodes that thread through the older psychiatric literature. Effect sizes are modest and the mechanistic link remains indirect. What there isn’t is a clean clinical program built around PEA itself, because the PK problem has always redirected pharmaceutical development toward more stable TAAR1 agonists rather than the endogenous parent compound.

We think the bench value here is real but narrow. If you’re running a TAAR1 biology program, you need PEA as your endogenous reference; it’s what every TAAR1 paper anchors comparisons against. That’s genuine utility and we credit it. But if you’re not specifically in the trace amine space, the compound adds little that a better-designed synthetic probe couldn’t do more cleanly. The supplement community has built a reputation around it that the pharmacological picture doesn’t support, and we score accordingly.

Novelty

28

Mechanism promise

60

In-category differentiation

38

Evidence quality

44

Translational signal

28

Research bench value

52

Rationale PEA scores on mechanism interest because TAAR1 is a genuinely active research target with real pharma investment, but its extremely short half-life and the availability of superior synthetic TAAR1 probes constrain bench value to the narrow endogenous-reference role; supplement-market hype inflates its reputation well past the pharmacological reality.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous trace amine / TAAR1 agonist

An endogenous trace amine; a TAAR1 agonist found at low concentrations in mammalian brain; structurally the parent of amphetamine.

Abstract

Beta-phenylethylamine (PEA; 2-phenylethylamine; CAS 64-04-0; molecular formula C8H11N; molecular weight 121.18) is an endogenous trace amine produced by decarboxylation of L-phenylalanine. The compound is found at low concentrations in mammalian brain (nM range) and in dietary sources including chocolate, cheese, and certain fermented foods. PEA is the prototype TAAR1 agonist (Ki approximately 700 nM at human TAAR1) with secondary effects on monoamine release and inhibition of MAO-B. Plasma half-life is extremely short (approximately 5 to 10 minutes) owing to rapid MAO-B-mediated degradation; exogenous oral PEA is therefore largely inactive without MAO-B inhibition (selegiline combination is used to extend duration). Behavioral and physiological effects parallel amphetamine but with shorter duration and lower potency. Used as the canonical endogenous TAAR1 agonist in trace amine research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-335Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
NG2-101

Plain-language summaryIntrigue 30 / 100

NG2-101 is an investigational neurogenic peptide. Limited published research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

20/100

Vendor-marketed neurogenic peptide with no disclosed sequence, no peer-reviewed data, and no verifiable mechanism

Look, the neurogenesis research space is genuinely interesting. BDNF and NGF pathway modulation, adult hippocampal neurogenesis as a therapeutic lever, the TrkB agonism story coming out of groups like Bhanu Bhanu, Moses Bhanu at UT Southwestern, NSI-189’s serotonergic angle. There’s real science here, and we wouldn’t pretend otherwise. The problem is that NG2-101 is not a participant in that science. It’s a vendor label attached to a compound with no disclosed amino acid sequence, no published pharmacology, and no peer-reviewed characterization of any kind.

Here’s the thing about scoring a compound like this: you can’t reward proximity to an interesting class when the compound itself is a black box. We don’t know what NG2-101 actually is. The mechanism claim, BDNF or NGF mimetic-like activity on hippocampal neurogenesis, is plausible as a concept, but plausibility borrowed from established biology isn’t mechanism evidence. Without a sequence, you can’t even design a meaningful experiment around it. Without published pharmacokinetic data, you don’t know if it crosses the blood-brain barrier, what its half-life is, or whether it degrades before reaching target tissue. Those aren’t minor gaps. Thats the entire foundation of a research program.

Evidence quality is essentially zero. Not single-lab, not preliminary, not contested. There is no published primary literature to contest. Vendor-supplied efficacy claims with no institutional affiliation, no DOI, and no identifiable investigator group behind them don’t register on the evidence axis. The distinction matters: BPC-157 has one dominant lab but it’s a real lab, with identifiable authors, peer-reviewed papers, and a replicable model system. NG2-101 doesn’t even clear that bar.

Bench value follows directly. An uncharacterized compound cannot serve as a pharmacological probe because you cant control what you cant identify. If you’re asking a question about TrkB signaling, you use 7,8-DHF or a validated TrkA/TrkB antibody; if you’re looking at BDNF pathway biology, you use recombinant BDNF or LM22A-4 with established binding constants. NG2-101 offers no comparable experimental handle. Investigators running neurogenesis programs would spend more time characterizing this compound than doing science with it, and even that characterization work wouldn’t be publishable without sequence disclosure.

We’re not dismissing neurogenic peptide research. We think it’s one of the more interesting spaces in cognitive biology right now. But a vendor label isn’t a research compound, and scoring it as one would be doing a disservice to investigators who need accurate signal about where to put their bench time. Obtain analytical confirmation before any investigational use, and treat efficacy claims with proportionate skepticism.

Novelty

35

Mechanism promise

30

In-category differentiation

15

Evidence quality

8

Translational signal

8

Research bench value

12

Rationale NG2-101 scores near-floor on evidence, translational signal, and bench value because there is literally nothing to evaluate: no published sequence, no peer-reviewed characterization, and no replication outside vendor claims. The claimed neurogenesis space is legitimately interesting, which buoys novelty and mechanism slightly, but those scores reflect the concept being borrowed rather than any actual compound-level work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Investigational neurogenic peptide

An investigational peptide for hippocampal neurogenesis with limited public characterization.

Abstract

NG2-101 is a research peptide marketed for neurogenic applications with limited published characterization. The compound’s specific sequence and mechanism are not fully disclosed in peer-reviewed literature; vendor claims center on hippocampal neurogenesis effects similar to BDNF or NGF mimetics. The absence of peer-reviewed characterization is significant; investigators should treat the compound with substantial skepticism and obtain analytical confirmation of identity and purity before any investigational use. There is no formal pharmacokinetic, safety, or efficacy data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-140Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cycloprolylglycine (CPG)

Plain-language summaryIntrigue 60 / 100

Cycloprolylglycine (CPG) is a cyclic dipeptide your body produces naturally and stores in spinal fluid. It is the active metabolite of noopept; when you take noopept your body converts it to CPG, which does most of the work. Researchers study it on its own to understand brain mechanisms. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

48/100

Endogenous noopept metabolite with real probe value but thin, consortium-concentrated evidence

Look, CPG sits in an unusual position. It’s not a synthetic nootropic with an invented mechanism; it’s an endogenous cyclic dipeptide that shows up in human CSF and brain tissue, which immediately gives it biological legitimacy that most research peptides don’t have. The story here is that noopept, a compound with real but messy pharmacology, gets hydrolyzed in vivo, and what the body actually does with it is partly form CPG. So if you want to understand what noopept is actually doing at the receptor level, CPG is the probe that lets you ask that question cleanly, without the prodrug pharmacology confounding the read.

The mechanism overlaps substantially with noopept: BDNF and NGF upregulation, modulation of NMDA and AMPA receptor expression, some antioxidant activity, modest cholinergic facilitation. None of these are individually paradigm-shifting. Neurotrophin upregulation is a crowded mechanism space, and glutamate receptor modulation has been worked from every direction for decades. What’s interesting is the combination, and particularly the idea that an endogenous molecule is doing this at all. That raises a real question: is CPG part of a broader endogenous regulatory loop for synaptic plasticity? Thats a legitimate thing to want to know.

Here’s the problem though: the evidence base is thin and geographically concentrated. The foundational work comes from Voronina, Gudasheva, and collaborators at the Zakusov Institute, the same group that developed noopept. That’s not inherently disqualifying, they’re serious pharmacologists with peer-reviewed output, but independent replication of the CPG-specific findings is sparse. We’re largely in single-consortium territory, which is exactly where you have to be cautious about effect size inflation and publication bias. The rodent data is real, but the human-relevant story for CPG as a standalone is essentially absent. You can extrapolate cautiously from the noopept clinical literature, but that’s not the same thing.

What we actually like about CPG is the bench value proposition. If your lab is studying endogenous cyclic dipeptide signaling in the CNS, or running noopept mechanism work and want to separate prodrug effects from active metabolite effects, CPG is the compound you need. Thats a real use case, even if its narrow. The translational arrow is weak right now, there’s no serious human program for CPG as a standalone compound, but as a tool for investigators who already have a reason to care about this mechanism space, it earns a spot in a serious research library.

We see CPG as a legitimate niche probe with an interesting endogenous angle, modest but real mechanism, weak evidence base, and genuine utility for a small set of investigators. Don’t prioritize it unless noopept mechanism work or endogenous cyclic dipeptide biology is central to your program. If it is, it belongs on your list.

Novelty

62

Mechanism promise

58

In-category differentiation

48

Evidence quality

30

Translational signal

25

Research bench value

60

Rationale CPG earns points on novelty (endogenous CNS dipeptide recently characterized as an independent research entity) and bench probe value (isolates active-metabolite pharmacology from noopept prodrug effects), but the evidence base is heavily concentrated in the Gudasheva/Zakusov Institute group with minimal independent replication and essentially no human-specific efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous dipeptide / noopept metabolite

An endogenous dipeptide present in mammalian CSF; the principal active metabolite of noopept and a research probe for endogenous nootropic mechanisms.

Abstract

Cycloprolylglycine (CPG; cyclic Pro-Gly dipeptide) is an endogenous cyclic dipeptide identified in human cerebrospinal fluid and brain tissue. The compound is the principal active metabolite of noopept (formed by enzymatic cyclization after the parent compound’s hydrolysis) and has been investigated as an independent research probe. Pharmacology overlaps with noopept: BDNF and NGF upregulation, antioxidant effects, modulation of NMDA and AMPA receptor expression, modest cholinergic facilitation. CPG itself is sold as a research peptide for investigators studying the noopept mechanism without the parent compound’s prodrug pharmacology. Pharmacokinetics: plasma half-life ~2 hours; oral bioavailability presumed adequate. Doses are not formally established; rodent doses scale to micrograms per kilogram.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-200Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 10 11 12 13

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.